Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Protagonist Therapeutics : JPMorgan Downgrades Protagonist Therapeutics to Neutral From Overweight, Price Target at $49

09/20/2021 | 07:19am EDT


© MT Newswires 2021
All news about PROTAGONIST THERAPEUTICS, INC.
10/13PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics..
MT
10/13NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
10/12PROTAGONIST THERAPEUTICS : Shares Drop on Elevated Volume
MT
10/12PROTAGONIST THERAPEUTICS : JMP Securities Adjusts Price Target on Protagonist Therapeutics..
MT
10/12WALL STREET STOCK EXCHANGE : It's just a period of market normalization
10/12PROTAGONIST THERAPEUTICS : SVB Leerink Adjusts Protagonist Therapeutics' Price Target to $..
MT
10/12PROTAGONIST THERAPEUTICS : JPMorgan Upgrades Protagonist Therapeutics to Overweight From N..
MT
10/12PROTAGONIST THERAPEUTICS : to Present at the Jefferies Next Generation IBD Therapeutics Su..
PR
10/12ANALYST RECOMMENDATIONS : Cigna, Halliburton, Nike, Nio, Trex...
10/11Health Care Stocks Sliding in Late Monday Trading
MT
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 14,2 M - -
Net income 2021 -117 M - -
Net cash 2021 250 M - -
P/E ratio 2021 -11,7x
Yield 2021 -
Capitalization 1 426 M 1 426 M -
EV / Sales 2021 82,6x
EV / Sales 2022 28,7x
Nbr of Employees 101
Free-Float 98,6%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 29,99 $
Average target price 58,29 $
Spread / Average Target 94,4%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Donald A. Kalkofen Chief Financial Officer
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.48.76%1 426
MODERNA, INC.218.76%134 418
LONZA GROUP AG29.18%59 339
IQVIA HOLDINGS INC.40.38%48 194
SEAGEN INC.-0.17%31 811
CELLTRION, INC.-39.42%25 446